Board of Directors
Robert L. Zerbe, M.D.
Lead Director since October 2012; Director since January 2006
Dr. Zerbe is the CEO of QUATRx Pharmaceuticals Company, a venture-backed drug development company which he co-founded in 2000. Prior to his role at QUATRx, he held senior executive management positions with major pharmaceutical companies including Eli Lilly and Pfizer. During his tenure at Eli Lilly, his clinical research and development positions included Managing Director, Lilly Research Center U.K., and Vice President of Clinical Investigation and Regulatory Affairs. He joined Parke Davis in 1993 becoming Senior Vice President of Worldwide Clinical Research and Development. In this capacity, he led the clinical development programs for key products including Lipitor® and Neurontin®. Dr. Zerbe received his M.D. from the Indiana University School of Medicine and has completed post-doctoral work in internal medicine, endocrinology and neuroendocrinology at Indiana University and the National Institutes of Health. Dr. Zerbe currently serves on the boards of directors of one other public company, Optimer Pharmaceuticals, Inc., and two private companies, Metabolex, Inc. and Edgemont Pharmaceuticals. Dr. Zerbe’s qualifications to sit on the Board include his management positions at major pharmaceutical companies including the experience he gleaned in his clinic development roles.
Alan L. Rubino
Director since September 2005
Mr. Rubino has served as CEO and President of Emisphere Technologies, Inc. since September, 2012. Previously, Mr. Rubino served as the CEO and President of New American Therapeutics, CEO and President of Akrimax Pharmaceuticals, LLC., and President and COO of Pharmos Corporation. Mr. Rubino has continued to expand upon a highly successful and distinguished career that included Hoffmann-LaRoche, Inc. where he was a member of the U.S. Executive and Operating Committees and a Securities and Exchange Commission (SEC) corporate officer. During his Roche tenure, he held key executive positions in marketing, sales, business operations, supply chain and human resource management, and was assigned executive committee roles in marketing, project management, and globalization. Mr. Rubino also held senior executive positions at PDI, Inc. and Cardinal Health. He holds a BA in economics from Rutgers University with a minor in biology/chemistry and completed post-graduate educational programs at the University of Lausanne and Harvard Business School. Additionally, he serves on the Board of Rutgers University School of Business and the Lerner Center for Pharmaceutical Studies. Mr. Rubino’s qualifications to sit on the Board include his leadership roles in the life sciences industry in a wide range of positions, including positions focused on sales and marketing and SEC matters.
Director since August 2013
Heidi M. Hagen is formerly the Global Chief Operating Officer for SOTIO a.s. in Prague, CZ Republic with a US office in Boston, MA. She has an extensive and proven track record in leading operations and commercializing innovative technologies. Before joining SOTIO she worked for Dendreon for ten years as Senior Vice President of Operations, where she was responsible for technical operations, among other duties. Prior to joining Dendreon, she spent ten years with Immunex Corporation where she held various positions in drug development and supply/operations management. Heidi has a B.S. in Cell and Molecular Biology, M.S. in Bioengineering, and M.B.A. from the University of Washington.
Director since January 2015
Steven C. Gilman, Ph.D. has served as the Executive Vice President, Research & Development and Chief Scientific Officer for Cubist Pharmaceuticals since September 2010. From February 2008 until September 2010, Dr. Gilman served as Senior Vice President, Discovery & Non-Clinical Development and Chief Scientific Officer. Prior to joining Cubist, Dr. Gilman served as Chairman of the board of directors and CEO of ActivBiotics, a privately held biopharmaceutical company. Previously, Dr. Gilman worked at Millennium Pharmaceuticals, Inc., where he held a number of senior leadership roles including Vice President and General Manager, Inflammation, responsible for all aspects of the Inflammation business from early gene discovery to product commercialization. Prior to Millennium, he was Group Director at Pfizer Global Research and Development, where he was responsible for drug discovery of novel antibacterial agents as well as several other therapeutic areas. Dr. Gilman has also held scientific, business, and academic appointments at Wyeth, Cytogen Corporation, Temple Medical School, and Connecticut College. He currently serves on the board of directors of the Massachusetts Biotechnology Association and Inhibikase, Inc., a privately held biotechnology company. In addition, Dr. Gilman serves on the Science and Regulatory Executive Committee of PhRMA and the Penn State University Biotechnology Advisory Board. Dr. Gilman received his Ph.D. and M.S. degrees in microbiology from Pennsylvania State University, his post-doctoral training at Scripps Clinic and Research Foundation, and received a B.A. in microbiology from Miami University of Ohio.
Director since January 2015
Kevin McLaughlin is the Senior Vice President, Chief Financial Officer and Treasurer at Acceleron Pharma. He most recently served as Senior Vice President and Chief Financial Officer of Qteros, Inc., a cellulosic biofuels company. He was a co-founder of Aptius Education, Inc. and from 2007 through 2009 he worked as the Chief Operating Officer and a director. From 1996 through 2007, Mr. McLaughlin held several executive positions with PRAECIS Pharmaceuticals, Inc. He joined PRAECIS as their first Chief Financial Officer where he had responsibility for private financings, partnership financings, the company’s initial public offering and subsequent stock offering. Later, Mr. McLaughlin became COO, and then President and CEO, and he served as a member of the board of directors. In this capacity he was responsible for negotiating the sale of the company to GlaxoSmithKline. He began his career in senior financial roles at Prime Computer and Computervision Corporation. Mr. McLaughlin received a BS in business from Northeastern University and an MBA from Babson College.
Director since January 2015
Dr. Wotton serves as the President and CEO of Ocata Therapeutics, joining the company in July 2014. Prior to Ocata, Dr. Wotton had served as President and CEO of Antares Pharma Inc. (NASDAQ: ATRS), since October, 2008. Prior to joining Antares, Dr. Wotton was the CEO of Topigen Pharmaceuticals and prior to Topigen, he was the Global Head of Business Development of SkyePharma PLC. Earlier in his career he held senior level positions at Eurand International BV, Penwest Pharmaceuticals, Abbott Laboratories and Merck, Sharp and Dohme. Dr. Wotton is also past Chairman of the Emerging Companies Advisory Board of BIOTEC Canada. Dr. Wotton received his Ph.D. in pharmaceutical sciences from the University of Nottingham. In 2014 he was named New Jersey EY Entrepreneur of the Year in Life Sciences.
President & CEO
Nick joined Vericel in 2013 with more than twenty years of executive management and corporate development experience in the biopharmaceutical industry, including nearly a decade with Eli Lilly and Company. Most recently, Nick was President and Chief Executive Officer of Promedior, Inc. During his career, he has held a variety of executive positions of increasing responsibility in product development, pharmaceutical operations, sales and marketing, and corporate development. He has extensive experience in the acquisition, development and commercialization of therapies to treat fibrovascular, metabolic and cardiovascular diseases. During his tenure at Eli Lilly and Company, Nick held positions as Director of Strategy and Business Development for Lilly’s Diabetes Product Group and also served as a founding Managing Director of Lilly Ventures. Nick received his B.S.B.A. in Accounting, Magna Cum Laude, from the State University of New York at Buffalo and a J.D. degree, with Honors, from the Duke University School of Law.